Quick Answer
Eledon Pharmaceuticals, Inc. reported Cash and Equivalents of $22.81 million for fiscal year 2025.
Eledon Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $22.81M | +11.0% |
| 2024 | $20.55M | +345.6% |
| 2023 | $4.61M | -91.8% |
| 2022 | $56.41M | -33.5% |
| 2021 | $84.83M | -25.7% |
| 2020 | $114.19M | +1199.0% |
| 2019 | $8.79M | -32.2% |
| 2018 | $12.97M | -24.7% |
| 2017 | $17.23M | +1462.4% |
| 2016 | $1.10M | -95.4% |
| 2015 | $24.02M | -77.2% |
| 2014 | $105.26M | +231.5% |
| 2013 | $31.75M | +171.6% |
| 2012 | $11.69M | +418.9% |
| 2011 | $2.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.67M | -45.7% | -36.1% |
| June 30, 2025 | $5.74M | -78.0% | -32.4% |
| March 31, 2025 | $8.50M | +50.2% | -58.7% |
| December 31, 2024 | $20.55M | +345.6% | +204.4% |
| September 30, 2024 | $6.75M | +84.1% | -74.1% |
| June 30, 2024 | $26.04M | -36.4% | +360.5% |
| March 31, 2024 | $5.66M | -87.8% | +22.6% |
| December 31, 2023 | $4.61M | -91.8% | +25.8% |
- Eledon Pharmaceuticals, Inc. showed an increase of +11.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Eledon Pharmaceuticals, Inc.’s cash and equivalents has grown by 912.3% (from $2.25 million to $22.81 million).
- The most recent figure is from Eledon Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: